Unlocking Opportunity: Dominate The Bi/Multispecific Drug In The Oncology Market With Confidence Now Available. Tracks 870+ Organizations And 1,400+ Drugs Across The Full Bi/Multispecific Oncology Pipeline
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence" has been added to ResearchAndMarkets.com's offering.
Bi/Multispecific Drugs in Oncology Analytical Tool Delivers Near-Real-Time Intelligence for Oncology Drug Development
The rapidly evolving bi- and multispecific drug market is transforming oncology through precision targeting, immune activation and advanced therapeutic engineering. As competition intensifies and global pipelines expand, pharmaceutical companies, biotechnology developers, investors and research organizations need current, reliable intelligence to identify opportunities and support strategic decision-making.
During 2024/25, the oncology landscape added 278 new bi- and multispecific drugs and recorded more than 8,566 events across 2,120 drug programs. More than 800 drugs were associated with new events, highlighting the pace, scale and increasing complexity of bi- and multispecific drug development.
The Bi/Multispecific Drugs in Oncology Analytical Tool provides comprehensive, near-real-time competitive, clinical and business intelligence for this high-growth segment. Unlike static market reports, the web-based platform includes a full year of online access, continuous data updates, monthly pipeline alerts, new features and dedicated support.
Strategic Intelligence Across the Oncology Market
The platform enables users to monitor active organizations, emerging drug candidates, therapeutic targets, engineering technologies, biomarkers, clinical trials, combination therapies, licensing activity and investment trends. Data can be exported through presentation-ready graphs and tables, helping teams create high-impact reports, conduct competitive pipeline analysis and make evidence-based decisions more efficiently.
- Track the global competitive landscape, including companies, academic institutions, new drugs, targets and technology platforms. Identify licensing, partnership and acquisition opportunities using biotechnology developer profiles, business development and licensing contacts, academic projects and historical deal data. Evaluate clinical development programs using detailed trial intelligence covering dosage, resistance mechanisms, adverse events, food effects, phase and status progression, first-in-human studies, tumor stage and grade, and line of therapy. Analyze more than 3,000 biomarkers, including stratifying, predictive and pharmacodynamic markers, alongside companion diagnostic programs from early development through approval. Connect with key opinion leaders, scientific experts, oncology-focused investors and potential funding partners. Monitor developments presented at leading oncology and hematology conferences, including AACR, ASCO, ESMO and ASH.
AI-Enhanced Oncology Business and Clinical Intelligence
Powered by an award-winning, artificial intelligence-enhanced intelligence platform with more than 25 years of oncology expertise, the analytical tool supports business development, search and evaluation, competitive intelligence, clinical development and portfolio strategy. Its integrated oncology deal intelligence covers technologies, targets, companies, academic-commercial opportunities, licensing contacts and thousands of historical transactions.
Proprietary early success and failure indicators help users identify emerging clinical leaders and monitor changes across the competitive landscape. The platform also maps combination therapy strategies by target, modality, indication and trial stage, while integrated real-world evidence analytics support segmentation by drug modality, co-medication profile, biomarker cluster and development stage.
Extensive Bi/Multispecific Oncology Market Coverage
- More than 870 monitored organizations, including 743 corporate entities, 89 academic organizations, 90 startups, 38 cancer centers or hospitals, and 34 major pharmaceutical or biotechnology companies. More than 1,400 drugs, including over 420 discovery-stage programs, more than 1,130 preclinical programs, over 300 Phase 1 programs, more than 200 Phase 2 programs, 23 Phase 3 programs and 21 marketed therapies. 481 therapeutic targets, 167 tumor types, 1,481 clinical trials and 464 clinical biomarkers. 197 drugs evaluated in combination therapy programs. 350 deals recorded during the last five years and more than 1,800 business development and licensing contacts. 17 worldwide academic-commercial opportunity projects. More than 1,100 funding events during the last five years and intelligence on 231 leading investors.
Leading drug developers represented in the database include Amgen, Hoffmann-La Roche and Genentech, Johnson & Johnson, Xencor and Biocytogen. The most active countries covered include the United States, China, South Korea, the United Kingdom and Germany.
Continuous Support and Scalable Access
Users receive 24/7 support and access to a library of how-to training videos, best-practice guidance, competitive analysis resources and real-world user case studies. The platform is designed to support teams throughout the oncology drug development lifecycle, from early research and target assessment to clinical strategy, partnering, investment and commercialization.
The Bi/Multispecific Drugs in Oncology Analytical Tool is delivered as a web-based application compatible with major browsers and requires internet access. Organizations seeking broader oncology intelligence can renew their annual access or upgrade to 1stOncology, the full-service platform supporting comprehensive oncology drug development intelligence.
By combining current pipeline data, advanced analytics, clinical intelligence, business development resources and global market coverage, the Bi/Multispecific Drugs in Oncology Analytical Tool helps organizations anticipate competitive shifts, evaluate emerging opportunities and make faster, more informed decisions across the oncology sector.
Companies Featured
- Amgen Hoffmann-La Roche (incl. Genentech) J&J Xencor Biocytogen
For more information about this directory visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment